LGVN News and Press, Longeveron Inc. From 04/01/22

Clinical-stage biotech, Longeveron (NASDAQ:LGVN) has extended its gains in the pre-market Friday as Wall Street continues to cheer the publication of results from a Phase 1 trial for its Alzheimer’s disease candidate Lomecel-B. Currently, Longeveron (LGVN) has added 13% with the t...

Worries about dragging sales in a couple of sectors sparked declines in Thursday's midday action. Best Buy (BBY) suffered amid a recent fall in store traffic. Meanwhile, analyst downgrades weighed on PC makers Dell (DELL) and HP (HPQ). In other news, Baidu (BIDU) dropped on continuing worries...

Gainers: Longeveron (LGVN) +62%. Clovis Oncology (CLVS) +61%. Icosavax (ICVX) +26%. Integrated Media Technology (IMTE) +28%. SAB Biotherapeutics (SABS) +21%. Local Bounti (LOCL) +21%. CPS Technologies (CPSH) +18%. Vector Group (VGR) +17%. Nano-X Imaging (NNOX) +16%. Vertex Energy (VTNR) +16%....

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nio (NYSE: NIO ) stock is sliding lower on Thursday after rallying earlier this week and that has some investors wondering if the stock is a buy. Source: Robert Way / Shutterstock.com If you listen to analysts...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Longeveron (NASDAQ: LGVN ) stock is taking off on Thursday after the drugmaker published news related to an Alzheimer’s treatment. Source: Bukhta Yurii / Shutterstock.com That includes the peer-reviewe...

Gainers: Clovis Oncology CLVS +68%. Longeveron LGVN +36%. Icosavax (ICVX) +27%. Creative Medical Technology (CELZ) +25%. Nano-X Imaging NNOX +22%. Losers: Clarus Therapeutics CRXT -27%. Acutus Medical AFIB -18%. Vyant Bio VYNT -15%. Phree...

Buying Penny Stocks Today? Here’s What You Need to Know With another day of trading penny stocks and blue chips here, there is a lot for investors to know. Recently, we’ve seen a bullish streak with 4 days of gains in the market. However, in the last day or so, this sentim...

Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia among the elderly, accounting for between 60% and 80...

Clinical-stage biotech, Longeveron (NASDAQ:LGVN) has added 44% in the pre-market Thursday after announcing the peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B. The data were published in the Journal of the Alzheimer...

Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...